Serum HIV-1 p24 antibody, HIV-1 RNA copy number and CD4 lymphocyte percentage are independently associated with risk of mortality in HIV-1-infected children

AIDS

Volumn 13, Issue 1, 1999, Pages 31-39

  Mofenson, Lynne M ^d   Harris, D Robert ^e   Rich, Kenneth ^a   Meyer III, William A ^b   Read, Jennifer S ^e   Moye Jr , John ^e   Nugent, Robert P ^e   Korelitz, James ^e   Bethel, James ^e   Pahwasect, Savita ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^c NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e NONE

Author keywords

CD4 lymphocyte percentage; HIV 1 p24 antibody; HIV 1 RNA; Immune complex dissociated p24 antigen; Mortality; Pediatric HIV 1 infection

Indexed keywords

ANTIGEN P24; CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN; VIRUS RNA;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; GENE DOSAGE; HIV ANTIBODIES; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; RISK FACTORS; RNA, VIRAL;

EID: 0002561892     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199901140-00005     Document Type: Article

References (43)

1. 1. Truong C, Brand D, Mallet F, Roingeard P, Barin F: Comparison of antibody responses to different forms of HIV-1 core antigens by epitope mapping. J Med Virol 1997, 51:145-151.
2. 2. Allain JP, Laurian Y, Paul DA, et al.: Long-term evaluation of HIV antigen and antibodies to p24 and gp41 in patients with hemophilia: potential clinical importance. N Engl J Med 1987, 317:1114-1121.
3. 3. Goudsmit J, Lange JMA, Paul D, Dawson GJ: Antigenemia and antibody titers to core and envelope antigens in AIDS, AIDS-related complex and subclinical human immunodeficiency virus infection. J Infect Dis 1987, 155:558-560.
4. 4. DeWolf F, Lange JMA, Houweling JTM, et al.: Numbers of CD4+ cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men. J Infect Dis 1988, 158:615-622.
5. 5. McHugh TM, Stites DP, Busch MP, Krowka JF, Striker RB, Hollander H: Relation of circulating levels of human immunodeficiency virus (HIV) antigen, antibody to p24, and HIV-containing immune complexes in HIV-infected patients. J Infect Dis 1988, 158:1088-1091.
6. 6. Fahey JL, Taylor JMG, Detels R, et al. : The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990, 322:166-172.
7. 7. Fernandez-Cruz E, Desto M, Garcia Montes M, Longo N, Gonzales B, Zabay JM: Immunological and serological markers predictive of progression to AIDS in a cohort of HIV-infected drug users. AIDS 1990, 4:987-994.
8. 8. Sheppard HW, Ascher MS, McRae B, Anderson RE, Lang W, Allain JP: The initial immune response to HIV and immune system activation determine the outcome of HIV disease. J Acquir Immune Defic Syndr 1991, 4:704-712.
9. 9. Farzadegan H, Chmiel JS, Odaka N, et al.: Association of antibody to human immunodeficiency virus type 1 core protein (p24), CD4+ lymphocyte number and AIDS-free time. J Infect Dis 1992, 166:1217-1222.
10. 10. Zwart G, van der Hoek L, Valk M, et al.: Antibody responses to HIV-1 envelope and Gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression. Virology 1994, 201:285-293.
11. 11. Strathdee SA, Frank JW, McLaughlin J, et al.: Quantitative measures of human immunodeficiency virus-specific antibodies predict progression to AIDS. J Infect Dis 1995, 172:1375-1379.
12. 12. Hogervorst E, Jurrians S, de Wolf F, et al.: Predictors for non-and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J Infect Dis 1995, 171:811-821.
13. 13. Chargelegue D, Stanley CM, O'Toole CM, Colvin BT, Steward MW: The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression. Clin Exp Immunol 1995, 99:175-181.
14. 14. Morand-Joubert L, Bludau H, Lerable J, Petit JC, Lefrere JJ: Serum anti-p24 antibody concentration has a predictive value on the decrease of CD4 lymphocyte count higher than acid-dissociated p24 antigen. J Med Virol 1995, 47:87-91.
15. 15. Henrard DR, Daar E, Farzadegan H, et al.: Virologic and immunologic characterization of symptomatic and asymptomatic primary HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 9:306-310.
16. 16. Farzadegan H, Henrard DR, Kleeberger CA, et al.: Virologic and serologic markers of rapid progression to AIDS after HIV-1 seroconversion. J Acquir Immune Defic Syndr 1996, 13:448-455.
17. 17. Sciascia C, Palomba E, Gay V, Tovo P-A: Anti HIV-1 antibody avidity is correlated with clinical status in infected children. Pediatric AIDS HIV Infect Fetus Adolesc 1996, 7:14-19.
18. 18. Henrard D, Fauvel M, Samson J, et al.: Ontogeny of the humoral immune response to human immunodeficiency virus type 1 in infants. J infect Dis 1993, 168:288-291.
19. 19. National Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group: Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic immunodeficiency virus infection. N Eng J Med 1991, 325:73-80.
20. 9/1 or more: effect on viral, opportunistic and bacterial infections. JAMA 1992, 268:483-488.
21. 21. Mofenson LM, Korelitz J, Meyer WA III, et al.: The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. J Infect Dis 1997, 175:1029-1038.
22. 22. Mofenson LM, Bethel J, Moye J, Flyer P, Nugent R, for the National Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group: Effect of intravenous immunoglobulin (IVIG) on CD4+ lymphocyte decline in HIV-infected children in a clinical trial of IVIG infection prophylaxis. J Acquir Immune Defic Syndr 1993, 6:1103-1113.
23. 23. Centers for Disease Control and Prevention: 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994, 43 (RR-12):1-10.
24. 24. Lin HJ, Myers LE, Yen-Lieberman B, et al.: Multicenter evaluation of quantitative methods for plasma human immunodeficiency virus type 1 RNA. J Infect Dis 1995, 170:553-562.
25. 25. US Department of Health and Human Services: AIDS Clinical Trials Group Virology Manual for HIV Laboratories, Vol. 4. Publication No. NIH-94-3828. Bethesda: National Institutes of Health; 1994.
26. 26. Hammer S, Crumpacker C, D'Aquila R, et al.: Use of virologic assays for detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS Clinical Trials Group Virology Committee. J Clin Microbiol 1993, 31:2557-2564.
27. 27. Weber JN, Weiss RA, Roberts C, et al.: Human immunodeficiency virus infection in two cohorts of homosexual men: neutralizing sera and association of anti-gag antibody with prognosis. Lancet 1987, i:119-122.
28. 28. Binley JM, Klasse PJ, Cao Y, et al. : Differential regulation of the antibody responses to gag and env proteins of human immunodeficiency virus type 1. J Virol 1997, 71:2799-2809.
29. 29. Teeuwsen VJP, Lange JMA, Keet R, et al : Low numbers of functionally active B lymphocytes in the peripheral blood of HIV-1-seropositive individuals with low p24-specific antibody titers. AIDS 1991, 5:971-979.
30. 30. Glushakova S, Grivel J-C, Fitzgerald W: Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency. Nat Med 1998, 4:346-349.
31. 31. Shearer GM, Clerici M: Early T-helper cell defects in HIV infection. AIDS 1991, 5:245-253.
32. 32. Lucey DR, Melcher GP, Hendrix CW, et al.: Human immunodeficiency virus infection in the US Air Force: seroconversions, clinical staging, and assessment of T helper cell functional assay to predict change in CD4 + T cell counts. J Infect Dis 1991, 164:631-637.
33. 33. Petersen J, Church J, Comperts E, Parkman R: Lymphocyte phenotype does not predict immune function in pediatric patients infected with human immunodeficiency virus type 1. J Pediatr 1989, 115:944-948.
34. 34. Roilides E, Clerici M, DePalma L, Rubin M, Pizzo PA, Shearer GM: Helper T-cell responses in children infected with human immunodeficiency virus type 1. J Pediatr 1991, 118:724-730.
35. 35. Clerici M, Roilides E, Butler KM, et al.: Changes in T-helper cell function in human immunodeficiency virus-infected children during didanosine therapy as a measure of antiretroviral activity. Blood 1992, 80:2196-2200.
36. 36. Rosenberg ES, Billingsley JM, Callendro AM, et al.: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997, 278:1447-1450.
37. 37. Williams IG, Gabriel G, Kelly G, Loveday C, Tedder RS, Weller IVD: Response of serum p24 antigen and antibody to p24 antigen in patients with AIDS and AIDS-related complex treated with zidovudine. AIDS 1990, 4:909-912.
38. 38. Melvin AJ, Mohan KM, Arcuino LAM, Edelstein RE, Frenkel LM: Clinical, virologic and immunologic responses of children with human immunodeficiency virus type 1 disease treated with protease inhibitors. Pediatr Infect Dis J 1997, 16:968-974.
39. 39. Mueller BU, Nelson RP, Sleasman J, et al.: A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection. Pediatrics 1998, 101:335-343.
40. 40. Rutstein RM, Feingold A, Meislich D, Word B, Rudy B: Protease inhibitor therapy in children with perinatally acquired HIV infection. AIDS 1997, 11:F107-F111.
41. 41. Yogev R, Stanley K, Nathman S, et al. : Virologic efficacy of ZDV + 3TC vs d4T + ritonavir vs ZDV + 3TC + ritonavir in stable antiretroviral experienced children. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September-October 1997 [abstract LB6].
42. 42. Pakker NG, Roos MTL, van Leeuwen R, et al: Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. J Acquir Immune Defic Syndr 1997, 16:318-326.
43. 43. Connors M, Kovacs JA, Krevat S, et al.: HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4 + T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997, 3:533-540.